Related Experiment Video
Updated: Jun 6, 2025
12:16
A Syngeneic Mouse B-Cell Lymphoma Model for Pre-Clinical Evaluation of CD19 CAR T Cells
Published on: October 16, 2018
14.7K
CBL-B - An upcoming immune-oncology target
Riccardo Fusco1, Zeinab Saedi1, Imma Capriello1
1Institute of Molecular and Translational Medicine, Faculty of Medicine and Dentistry, and Czech Advanced Technology and Research Institute, Palacky University, Olomouc, Czechia.
Expert Opinion on Therapeutic Patents
|November 25, 2024
Summary
The E3 ubiquitin ligase Cbl-b, a novel immune-oncology target, regulates T-cell activation. Inhibiting Cbl-b shows promise for enhancing cancer immunotherapy and overcoming tumor-induced immunosuppression.
Area of Science:
- Immuno-oncology
- Cancer immunotherapy
- Ubiquitin ligase signaling
Background:
- Cbl-b (E3 ubiquitin ligase) is crucial for T-cell activation and immune homeostasis.
- Cbl-b activity contributes to an immunosuppressive tumor microenvironment.
- Cbl-b regulates key signaling proteins via ubiquitination and degradation.
Purpose of the Study:
- To review small molecules and antibody-drug conjugates targeting Cbl-b from 2018-2024.
- To analyze the therapeutic potential of Cbl-b inhibition in cancer immunotherapy.
- To explore Cbl-b as a target beyond PDL1/PD1 inhibition.
Main Methods:
- Patent literature review from 2018 to 2024.
- Utilized publicly available patent databases.
- Applied an in-house developed cheminformatic workflow for analysis.
Main Results:
- Identified and reviewed small molecules and antibody-drug conjugates targeting Cbl-b.
- Analysis of patents highlights ongoing development in Cbl-b inhibitor research.
- Evidence of clinical advancement and ongoing trials for Cbl-b inhibitors.
Conclusions:
- Targeting Cbl-b offers a novel strategy in immuno-oncology.
- Cbl-b inhibition shows potential to enhance cancer immunotherapy outcomes.
- Strategic inhibition of Cbl-b represents a significant advancement in cancer treatment.
Related Concept Videos
02:57Targeted Cancer Therapies
7.5K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.5K
01:27Tumor Immunotherapy
480
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
480
01:24B Cell Activation and Differentiation
1.6K
The adaptive immune response, a sophisticated defense mechanism, relies on the activation and differentiation of B lymphocytes, or B cells. These processes enable our bodies to mount a tailored response against specific pathogens such as bacteria, free virus particles, toxins, and parasites.
When naive B cells encounter a specific antigen that can bind to the B cell receptor (BCR) on their surface, they undergo sensitization to respond to the antigen's presence. Sensitization begins with...
When naive B cells encounter a specific antigen that can bind to the B cell receptor (BCR) on their surface, they undergo sensitization to respond to the antigen's presence. Sensitization begins with...
1.6K
01:27Cytotoxic T Cells-mediated Immune Response
849
Cytotoxic T cells are a vital component of the immune system. They have the remarkable ability to identify and target antigens on infected or abnormal cells. These antigens often originate from intracellular pathogens such as viruses or abnormal proteins cancer cells produce.
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
849
02:50Combination Therapies and Personalized Medicine
4.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K